KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemed (CHE) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Chemed (CHE) over the last 16 years, with FY2024 value amounting to $178.4 million.

  • Chemed's Cash & Equivalents fell 4558.55% to $129.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.8 million, marking a year-over-year decrease of 4558.55%. This contributed to the annual value of $178.4 million for FY2024, which is 3243.24% down from last year.
  • Chemed's Cash & Equivalents amounted to $178.4 million in FY2024, which was down 3243.24% from $264.0 million recorded in FY2023.
  • Chemed's Cash & Equivalents' 5-year high stood at $264.0 million during FY2023, with a 5-year trough of $32.9 million in FY2021.
  • In the last 5 years, Chemed's Cash & Equivalents had a median value of $162.7 million in 2020 and averaged $142.4 million.
  • In the last 5 years, Chemed's Cash & Equivalents surged by 254168.56% in 2020 and then crashed by 7977.87% in 2021.
  • Annual analysis of 5 years shows Chemed's Cash & Equivalents stood at $162.7 million in 2020, then tumbled by 79.78% to $32.9 million in 2021, then surged by 125.34% to $74.1 million in 2022, then surged by 256.09% to $264.0 million in 2023, then tumbled by 32.43% to $178.4 million in 2024.
  • Its Cash & Equivalents was $178.4 million in FY2024, compared to $264.0 million in FY2023 and $74.1 million in FY2022.